Holen Sie sich die Stockscreener-App
61.03
2.42%
1.44
Handel nachbörslich:
60.81
-0.22
-0.36%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CYTK?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$59.59
Offen:
$59.05
24-Stunden-Volumen:
2.17M
Relative Volume:
1.02
Marktkapitalisierung:
$7.30B
Einnahmen:
$18.47M
Nettoeinkommen (Verlust:
$-589.53M
KGV:
-11.60
EPS:
-5.26
Netto-Cashflow:
$-399.80M
1W Leistung:
+1.43%
1M Leistung:
+19.36%
6M Leistung:
+53.30%
1J Leistung:
+11.98%
1-Tages-Spanne:
$58.84
$61.58
1-Wochen-Bereich:
$58.58
$61.58
52-Wochen-Spanne:
$29.31
$61.58
Cytokinetics Inc Stock (CYTK) Company Profile
Firmenname
Cytokinetics Inc
Sektor
Branche
Telefon
(650) 624-3000
Adresse
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Vergleichen Sie CYTK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
61.03 | 7.13B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Fortgesetzt | Raymond James | Mkt Perform |
| 2025-04-24 | Eingeleitet | Barclays | Overweight |
| 2025-02-07 | Eingeleitet | Citigroup | Buy |
| 2025-01-22 | Eingeleitet | Stifel | Buy |
| 2024-11-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-13 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-07 | Eingeleitet | B. Riley Securities | Buy |
| 2023-08-15 | Eingeleitet | SVB Securities | Outperform |
| 2023-02-17 | Eingeleitet | BofA Securities | Neutral |
| 2022-12-23 | Bestätigt | Needham | Buy |
| 2022-12-20 | Eingeleitet | Truist | Buy |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-01-28 | Eingeleitet | Goldman | Buy |
| 2021-12-22 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-10 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2021-02-18 | Eingeleitet | Barclays | Overweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-29 | Eingeleitet | Goldman | Neutral |
| 2020-07-10 | Eingeleitet | Raymond James | Strong Buy |
| 2020-05-05 | Eingeleitet | Mizuho | Buy |
| 2020-04-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Bestätigt | Morgan Stanley | Overweight |
| 2017-11-22 | Herabstufung | Needham | Strong Buy → Buy |
| 2017-11-21 | Bestätigt | H.C. Wainwright | Buy |
| 2017-07-31 | Eingeleitet | Morgan Stanley | Overweight |
| 2017-03-08 | Eingeleitet | Rodman & Renshaw | Buy |
| 2017-02-06 | Hochstufung | Needham | Buy → Strong Buy |
| 2016-12-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Bestätigt | Needham | Buy |
| 2015-11-10 | Bestätigt | FBR Capital | Outperform |
| 2015-11-09 | Bestätigt | ROTH Capital | Buy |
| 2015-07-24 | Bestätigt | MLV & Co | Buy |
| 2014-12-31 | Bestätigt | ROTH Capital | Buy |
| 2014-11-04 | Hochstufung | MLV & Co | Hold → Buy |
| 2014-04-28 | Bestätigt | Needham | Buy |
Alle ansehen
Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Cytokinetics, - GlobeNewswire
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before ... - Caledonian Record
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CYTK - GlobeNewswire Inc.
Class Action Filed Against Cytokinetics, Incorporated - GlobeNewswire
Recover Investment Losses: Class Action Initiated Against Cytokinetics, Incorporated (CYTK) - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cytokinetics, Incorporate of Class Action Lawsuit and Upcoming DeadlinesCYTK - PR Newswire
Is Cytokinetics Incorporated forming a bottoming base2025 Market Overview & Capital Efficiency Focused Strategies - newser.com
Is it time to cut losses on Cytokinetics Incorporated2025 Performance Recap & High Conviction Investment Ideas - newser.com
Aberdeen Group plc Buys 320,508 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Securities Lawsuit Alert: Cytokinetics, Incorporated (CYTK)Contact Levi & Korsinsky Before November 17, 2025 - ACCESS Newswire
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Cytokinetics, Incorporated Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - FinancialContent
Cytokinetics, Incorporated $CYTK Stake Increased by Mirae Asset Global Investments Co. Ltd. - Defense World
Bragar Eagel & Squire, P.C. Reminds Investors of VFC, Cytokinetics, Quanex, and RCI to Contact the Firm About their Rights in Filed Class Action Lawsuits - GlobeNewswire
ROSEN, LEADING INVESTOR RIGHTS COUNSEL, Encourages - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors of VFC, - GlobeNewswire
Shareholders of Cytokinetics, Incorporated (CYTK): Protect Your Rights Before November 17, 2025Contact Levi & Korsinsky - ACCESS Newswire
Investors who lost money on Cytokinetics, Incorporated(CYTK) should contact Levi & Korsinsky about pending Class ActionCYTK - PR Newswire
State of Alaska Department of Revenue Decreases Stake in Cytokinetics, Incorporated $CYTK - Defense World
Weiss Ratings Reiterates "Sell (D-)" Rating for Cytokinetics (NASDAQ:CYTK) - MarketBeat
CYTK SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics - PR Newswire
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionCYTK - Eastern Progress
Cytokinetics, Inc. Hits New 52-Week High at USD 61.42 - Markets Mojo
Portnoy Law Firm Announces Class Action on Behalf of Cytokinetics, Incorporated. Investors - GlobeNewswire
Deadline Alert: Cytokinetics, Incorporated (CYTK) - GlobeNewswire
Cytokinetics, Incorporated Sued for Securities Law Violations - GuruFocus
How Cytokinetics Incorporated stock benefits from tech adoptionTreasury Yields & AI Enhanced Market Trend Forecasts - newser.com
Top chart patterns to watch in Cytokinetics IncorporatedWeekly Stock Report & Step-by-Step Swing Trade Plans - newser.com
Should I hold or sell Cytokinetics Incorporated stock in 2025July 2025 Summary & Low Drawdown Trading Strategies - newser.com
Duchenne Muscular Dystrophy Drugs Market Global Forecast 2025-2032: Sarepta, Pfizer, BioMarin, Roche, Bayer, Solid Biosciences, Cytokinetics, and NS Pharma Drive Innovation and Commercial Expansion - Yahoo
Cytokinetics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
Cytokinetics’ SWOT analysis: aficamten’s potential reshapes HCM treatment landscape - Investing.com
Cytokinetics, Inc. Hits New 52-Week High at $61.00 - Markets Mojo
Cytokinetics Shareholder Alert By Former Louisiana Attorney - GlobeNewswire
Insider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics (NASDAQ:CYTK) EVP Fady Ibraham Malik Sells 2,000 Shares - MarketBeat
ROSEN, LEADING INVESTOR COUNSEL, Encourages Cytokinetics, - GlobeNewswire
Malik, Cytokinetics evp, sells $121k in shares - Investing.com
Key facts: Pomerantz LLP filed a class action lawsuit against Cytokinetics on October 6-7, 2025, alleging securities fraud. Investors can apply to be Lead Plaintiff until November 17, 2025. - TradingView
Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
December 19th Options Now Available For Cytokinetics (CYTK) - Nasdaq
CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm - PR Newswire
Robbins LLP Reminds Cytokinetics, Inc. Investors of the Upcoming - GuruFocus
Robbins LLP Reminds Cytokinetics, Inc. Investors of the Upcoming Lead Plaintiff Deadline in the Class Action Against CYTK - PR Newswire
Insider Sell: Kaye Edward M. MD Sells 6,757 Shares of Cytokineti - GuruFocus
Lost Money on Cytokinetics, Incorporated (CYTK)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - GlobeNewswire
Investors in Cytokinetics, Incorporated (CYTK): Protect Your RightsContact Levi & Korsinsky Before November 17, 2025 - ACCESS Newswire
Cytokinetics (NASDAQ:CYTK) Hits New 12-Month HighShould You Buy? - MarketBeat
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Cytokinetics, Incorporated Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit | FinancialContent - FinancialContent
Cytokinetics stock hits 52-week high at 59.5 USD - Investing.com
Cytokinetics stock hits 52-week high at 59.5 USD By Investing.com - Investing.com Australia
Barclays Raises Price Target for Cytokinetics (CYTK) to $82 | CY - GuruFocus
Finanzdaten der Cytokinetics Inc-Aktie (CYTK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cytokinetics Inc-Aktie (CYTK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
Oct 07 '25 |
Sale |
60.56 |
2,000 |
121,120 |
140,610 |
| Kaye Edward M. MD | Director |
Oct 06 '25 |
Sale |
60.00 |
6,757 |
405,420 |
9,778 |
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):